Gliomas are the most common form of malignant primary brain tumour. In the past year, substantial progress has been made in the classification and treatment of lower-grade gliomas (WHO grades II and III), and the FDA has approved a new therapy for newly diagnosed glioblastomas.
This is a preview of subscription content, log in via an institution to check access.
References
Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumours diagnosed in the United States in 2008–2012. Neuro Oncol. 17 (Suppl. 4), iv1–iv62 (2015).
Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97–109 (2007).
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized Phase III clinical trial. J. Clin. Oncol. 31, 4085–4091 (2013).
Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458–468 (2015).
Eckel-Passow, J. E. et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumours. N. Engl. J. Med. 372, 2499–2508 (2015).
Buckner, J. et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG [abstract]. J. Clin. Oncol. 32 (Suppl. 5), 2000 (2014).
Buckner, J. et al. R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: results by histologic type. Neuro Oncol. 16 (Suppl. 5), v11 (2014).
Stupp, R. et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 314, 2535–2543 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.Y.W. and D.A.R. serve on the advisory board of Novocure.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Wen, P., Reardon, D. Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol 12, 69–70 (2016). https://doi.org/10.1038/nrneurol.2015.242
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.242
- Springer Nature Limited
This article is cited by
-
miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review
Journal of the Egyptian National Cancer Institute (2024)
-
A bis-boron boramino acid PET tracer for brain tumor diagnosis
European Journal of Nuclear Medicine and Molecular Imaging (2024)
-
Construction and Verification of an RNA-Binding Protein-Associated Prognostic Model for Gliomas
Current Medical Science (2023)
-
CircRNA circ_POSTN promotes the malignancy of glioma by regulating the miR-433-3p/SPARC axis
Metabolic Brain Disease (2023)
-
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Cancer Immunology, Immunotherapy (2023)